Full Article at IIR has reaffirmed its Recommended rating for PIA after undertaking a review post the appointment of a new Portfolio Manager, Harding Loevner. The full report can be found on the IIR website. On 26 July 2021, Pengana International Equities Limited (PIA) announced a fully franked dividend of 1.35 cents per share for the June quarter. This represents an 8% increase on the March quarter dividend and takes the total dividends declared for FY21 of 5.1 cents per share, fully franked....
Akorn Provides Second Quarter 2020 Results LAKE FOREST, Ill., Aug. 07, 2020 (GLOBE NEWSWIRE) -- Akorn, Inc. (The OTC Pink Market: AKRXQ), a leading specialty pharmaceutical company, today announced its financial results for the second quarter of 2020. Second Quarter 2020 Results and Recent Developments Net revenue was $120 million, down $58 million, 32% from the prior year quarterNet loss was $69 million, compared to $112 million loss in the prior year quarterAdjusted EBITDA was $(2) million, compared to $36 million in the prior year quarterFiled for Chapter 11 bankruptcy protection on ...
Akorn Animal Health Announces Launch of Neomycin and Polymyxin B Sulfates, and Bacitracin Zinc Ophthalmic Ointment LAKE FOREST, Ill., June 22, 2020 (GLOBE NEWSWIRE) -- Akorn, Inc. (OTC Pink Market: AKRXQ), a leading specialty generic pharmaceutical company, today announced the launch of its Abbreviated New Animal Drug Application (ANADA) for Neomycin and Polymyxin B Sulfates, and Bacitracin Zinc Ophthalmic Ointment, USP (BNP). The product is manufactured at Akorn’s Somerset, New Jersey manufacturing site. Douglas Boothe, Akorn’s President and Chief Executive Officer, stated, “This is an ...
Rating Action: Moody's downgrades Akorn's PDR to D-PD following Chapter 11 filing. Global Credit Research- 26 May 2020. New York, May 26, 2020-- Moody's Investors Service downgraded Akorn, Inc.' s Probability of Default Rating to D-PD from Ca-PD.
Akorn Provides First Quarter 2020 Results LAKE FOREST, Ill., May 11, 2020 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq: AKRX), a leading specialty pharmaceutical company, today announced its financial results for the first quarter of 2020. First Quarter 2020 Results and Recent Developments Net revenue was $205 million, up $39 million, 23% from the prior year quarterNet loss was $257 million, compared to $82 million loss in the prior year quarterAdjusted EBITDA was $59 million, compared to $23 million in the prior year quarterDiscussions with lenders regarding the sale process and Chapter 11 ...
Akorn Provides Fourth Quarter and Full Year 2019 Results LAKE FOREST, Ill., Feb. 26, 2020 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq: AKRX), a leading specialty pharmaceutical company, today announced its financial results for the quarter and year ended December 31, 2019. Fourth Quarter 2019 Results and Recent Developments Net revenue was $162 million, an increase of $9 million, or 5.8%, compared to the fourth quarter of 2018.Net loss was $81 million compared to a net loss of $215 million in the fourth quarter of 2018.Adjusted EBITDA was $18 million compared to $(20) million in the fourth ...
Rating Action: Moody's downgrades Akorn's CFR to Caa3; outlook stable. Global Credit Research- 20 Feb 2020. New York, February 20, 2020-- Moody's Investors Service downgraded the ratings of Akorn, Inc. including the Corporate Family Rating to Caa3 from Caa1, the Probability of Default Rating to Ca-PD from Caa1-PD, and the senior secured term loan rating to Caa3 from Caa1.
Announcement of Periodic Review: Moody's announces completion of a periodic review of ratings of Akorn, Inc.. Global Credit Research- 14 Jan 2020. New York, January 14, 2020-- Moody's Investors Service has completed a periodic review of the ratings of Akorn, Inc. and other ratings that are associated with the same analytical unit.
Akorn Announces Extension of Standstill Agreement LAKE FOREST, Ill., Dec. 16, 2019 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq: AKRX), a leading specialty pharmaceutical company, today announced that Akorn and certain of its lenders have reached an agreement that extends the standstill period to February 7, 2020. Doug Boothe, Akorn’s President and Chief Executive Officer, commented, “We are pleased to have reached this agreement, which provides additional time for Akorn, our Board of Directors, and advisors to evaluate strategic alternatives to address the Company’s litigation-related liab...
Akorn to Present at the Credit Suisse Healthcare Conference LAKE FOREST, Ill., Nov. 05, 2019 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq: AKRX), a leading specialty pharmaceutical company, today announced that management will present at the Credit Suisse 28th Annual Healthcare Conference on Wednesday, November 13, 2019 at 10:55 a.m. Mountain Time, in Scottsdale, Arizona. A live webcast of the presentation can be accessed in the investor relations portion of Akorn's website at . A replay of the webcast will be available at the same location for 90 days following the event. About AkornAkorn, ...
Akorn Provides Preliminary Third Quarter 2019 Results Updates net loss and affirms net revenue and adjusted EBITDA guidance LAKE FOREST, Ill., Oct. 31, 2019 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq: AKRX), a leading specialty pharmaceutical company, today announced its preliminary financial results for the third quarter of 2019. Third Quarter 2019 and Recent Business Highlights Net revenue was $176 million, up $11 million, 6% from the prior year quarterNet income was $48 million, compared to $70 million loss in the prior year quarterAdjusted EBITDA was $29 million, compared to $10 mill...
Akorn Receives FDA Approval for Betamethasone Dipropionate Lotion USP (Augmented), 0.05% LAKE FOREST, Ill., Oct. 14, 2019 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq: AKRX), a leading specialty pharmaceutical company, today announced that it received a new Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (FDA) for betamethasone dipropionate lotion USP (augmented), 0.05%. The product is manufactured at Akorn’s Amityville, New York manufacturing facility. According to IQVIA, U.S. sales of betamethasone dipropionate lotion (augmented), 0.05% were appro...
Akorn to Report Third Quarter 2019 Financial Results and Host Conference Call LAKE FOREST, Ill., Oct. 14, 2019 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq: AKRX), a leading specialty pharmaceutical company, today announced that it plans to issue a press release before market open on Thursday, October 31, 2019 outlining its third quarter 2019 financial results. In addition, the Company has scheduled a conference call at 10:00 a.m. ET on the same day to discuss its third quarter 2019 financial and operating results. Hosting the call will be Douglas Boothe, President and Chief Executive Officer...
The independent financial analyst theScreener just awarded an improved star rating to AKORN INCO. (US), active in the Pharmaceuticals industry. As regards its fundamental valuation, the title receives an improved star rating and now shows 4 out of 4 possible stars. With regard to its market behaviour, it remains unchanged and can be qualified as risky. theScreener considers that these elements allow slightly upgrading its rating to Neutral. As of the analysis date September 13, 2019, the closing...
Akorn Receives FDA Approval for Azelastine Hydrochloride Nasal Spray, 0.15% LAKE FOREST, Ill., Aug. 26, 2019 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq: AKRX), a leading specialty generic pharmaceutical company, today announced that it received a new Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (FDA) for Azelastine Hydrochloride Nasal Spray, 0.15%. The product is manufactured at Akorn’s Amityville, New York manufacturing facility. According to IQVIA, U.S. sales of Azelastine Hydrochloride Nasal Spray, 0.15% were approximately $18 million for t...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.